Empagliflozin 25 MG

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Empagliflozin in Acute Heart Failure

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation

SGLT2i, Hepatic Glucose Production, and SNS

SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia

SGLTi, Hepatic Glucose Production and Ketogenesis

Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease

Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease

Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus

Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention

To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults

Empagliflozin and Hepatic Glucose Metabolism

POST-CABGDM: Empagliflozin in Perioperative CABG

Effect of Empagliflozin on Ventricular Repolarization.

SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot